GlassScriptPhysician profile
Gurbaj Singh
NPI 1235593005
$1,576.32
in general payments reported to CMS, 2019-2025
17 companies · $422 in 2025
The $422 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.97 · 2021: $44.23 · 2022: $293 · 2023: $217 · 2024: $583 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $297.08 | 2023-2025 | Evenity, Repatha |
| Corcept Therapeutics | $195.31 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.62 | 2022-2024 | Jardiance |
| Dexcom, INC. | $152.30 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $151.25 | 2022-2024 | |
| Lilly USA, LLC | $105.35 | 2022-2024 | Mounjaro |
| Ascendis Pharma Endocrinology INC | $97.87 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $94.51 | 2024 | Rezdiffra |
| Novo Nordisk INC | $65.30 | 2022-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $62.20 | 2020-2021 | |
| Abbott Laboratories | $60.71 | 2022-2024 | Proclaim |
| Otsuka America Pharmaceutical, INC. | $27.41 | 2022 | |
| Insulet Corporation | $22.83 | 2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $22.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.69 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.10 | 2025 | |
| Nevro Corp. | $14.12 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurbaj Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.